Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TrAVeRse: Acalabrutinib + Venetoclax + Rituximab in Treatment-Naïve Mantle Cell Lymphoma
2023-505205-16-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of acalabrutinib, venetoclax and rituximab in mantle cell lymphoma (MCL) (2 arms), sponsored by AstraZeneca. Primary endpoint: MRD-negative complete response rate. Planned start Dec 2023; status: authorised.
02
Drugs
acalabrutinibvenetoclaxrituximab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2023-505205-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505205-16-00.